Stockreport

Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Neurogene Inc.  (NGNE) 
PDF NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected [Read more]